Table 2.

Summary of the mutational status of tumors included in the study population detected by the different techniques

CobasTherascreen PyroDigital PCR
N (%)N (%)N (%)
KRAS (exon 2)
 WT370 (63.46%)372 (63.81%)317 (54.37%)
 MUT209 (35.85%)208 (35.68%)261 (44.77%)
 NV4 (0.69%)3 (0.51%)5 (0.86%)
RAS (KRAS + NRAS, exons 2/3/4)
 WT306 (52.49%)304 (52.14%)245 (41.95%)
 MUT273 (46.83%)276 (47.34%)332 (57.02%)
 NV4 (0.68%)3 (0.51%)6 (1.03%)
RAS + BRAF
 WT283 (48.63%)275 (47.17%)223 (38.25%)
 MUT296 (50.68%)305 (52.32%)355 (60.89%)
 NV4 (0.69%)3 (0.51%)5 (0.86%)
RAS + BRAF + PIK3CA
 WT246 (42.2%)254 (43.57%)217 (37.22%)
 MUT331 (56.77%)325 (55.74%)361 (61.92%)
 NV6 (1.03%)4 (0.69%)5 (0.86%)
  • Abbreviations: WT, wild-type tumor; MUT, mutated tumor; NV, no valid results.